Performance evaluation study to evaluate comprehensive molecular diagnostics

One sample. All the answers.

NEO New Oncology GmbH initiated the diagnostic study “NEOlung” for lung cancer patients. Patients with advanced or metastatic stage non-small cell lung cancer (NSCLC) will hereby gain expedited access to the comprehensive molecular liquid biopsy diagnostics platform NEOliquid. The profile of detected genetic alterations as well as occurrence of resistance mechanisms will be assessed within the study, and patients will benefit from the comprehensive tumor profile that could provide valuable information for an informed treatment decision. NEOlung also includes a comparison of the NEO platform to standard methods, as well as the correlation of diagnostic data obtained from tissue and blood. NEO lung will be performed in several European countries, in Germany the clinical centers of the NOWEL network participate.



Office: +49.221.888.23 80


NEO New Oncology GmbH
Gottfried-Hagen-Str. 20
51105 Cologne

ImprintPrivacy policy uses cookies to make the website more user-friendly. By continuing to use the website, you agree to the use of cookies. If you do not agree to the storage of cookies, you will find further information HERE.